# Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies

> **NCT00544466** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 75 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** fludarabine phosphate
- **DRUG:** melphalan
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **RADIATION:** intensity-modulated radiation therapy

## Key facts

- **NCT ID:** NCT00544466
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2006-07-31
- **Primary completion:** 2013-08-01
- **Final completion:** 2026-12-02
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544466, "Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00544466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*